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The Centers for Disease Control and Prevention (CDC)
estimates that ~370,000 people in the United States rely on
hemodialysis care.1 Despite the publication of multiple
guidelines over the years, acquisition of hepatitis C virus
(HCV) continues to occur in dialysis centers. In this
commentary, we review recent outbreaks of hepatitis C in
hemodialysis centers and describe the breach of infection
control policies and procedures that were incriminated in
these outbreaks.
The reasons for continued outbreaks of HCV in dialysis
centers may be examined by reviewing the following factors:
(1) characteristics of HCV including prevalence, transmissi-
bility, and environmental stability; (2) the physical layout of
dialysis centers; (3) patient risk factors; and (4) failure
of healthcare personnel (HCP) to adhere to standards of
infection control.
features of hcv that favor
transmission in dialysis centers
Several features of HCV enhance the risk of transmission in
hemodialysis centers: (1) HCV infection is common in the
United States. (2) HCV is transmissible via needle sticks and
other parenteral exposures. (3) HCV is stable in the environ-
ment for days to weeks. (4) Most patients with HCV are
asymptomatic. The CDC estimates that there are 2.7 million
persons with chronic HCV infection in the United States.2
Transmission routes for HCV include infection drug use,
needle-stick injuries in healthcare, sharing personal items
contaminated with infectious blood (eg, razors), and other
healthcare procedures that involve invasive procedures such as
injections. The risk of transmission via a parenteral exposure
such as a needle stick is between 1% and 2%.3 A meta-analysis
reported the rate or transmission by needle sticks as 1.9%.4
Various studies have reported that HCV inoculated onto
surfaces survived at room temperature for up to 16 hours,5 up
to 5 days,6 and up to 6 weeks.7 HCV survived in tuberculin
syringes for up to 63 days.8 Importantly, ~70%–80% of
patients with HCV are asymptomatic.2,3 Thus, infection can
only be detected via diagnostic tests. Failure to obtain HCV
testing to identify infected persons may lead to decreased
attention to infection control in infected persons.
characteristics of dialysis centers
that enhance the possibility of hcv
transmission
A number of characteristics of hemodialysis centers and the
process of dialysis enhance the possibility of HCV transmis-
sion. (1) Patients are generally placed in bays separated from
other patients by a short distance. (2) Sinks may not be avail-
able in each bay. (3) HCP have frequent contact with blood-
containing devices. (4) Facilities may lack separate clean and
dirty utility rooms or a separate medication preparation area.
(5) Dialysis centers are usually free standing and do not have
immediate access to trained infection control preventionists.
(6) Dialysis machines and equipment are heavily blood
contaminated and must be disinfected with strict adherence
to manufacturer’s recommendations and sterilization/
disinfection guidelines.
patient characteristics that promote
transmission of hcv
Several patient characteristics promote transmission of HCV:
(1) Dialysis is prolonged and patients require venous access.
(2) Patients frequently receive medications via injection or
infusion. (3) Patients may be unable to fully participate in
their care.
infection control in hemodialysis
centers
Multiple studies have demonstrated that HCP in dialysis
centers are often poorly compliant with infection guidelines to
prevent HCV transmission in these settings.9,10 Shimokura et al9
used a cluster random survey design to study HCP in
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53 hemodialysis facilities in the United States in 2000. Only 57%
of these facilities reported that HCP always performed hand
hygiene (HH) and changed gloves before putting patients on
dialysis; 47% reported that HCP performed HH between
patient care stations; and 55% reported that HCP performed
HH between patients when administering intravenous medica-
tions,9 In a more detailed analysis, Shimokura et al10 reported
that the patient care practices independently associated with a
higher center prevalence of HCV included reusing priming
receptacles without disinfection (odds ratio [OR], 2.3), handling
blood specimens adjacent to medications and clean supplies
(OR, 2.2), and using mobile carts to deliver injectable medica-
tions (OR, 1.7). Independently related facility covariates were
≥10% patient HCV prevalence (OR, 3.0), patient-to-staff ratio
>7 to 1 (OR, 2.4), and treatment duration ≥2 years (OR, 2.4).
lessons from outbreaks of hcv in
hemodialysis centers
Outbreaks of HCV in hemodialysis centers continue to be
reported (Table 1).11–20 The papers in this issue by Nguyen
et al19 and Aho et al20 add to the growing body of knowledge
regarding the breaches in infection control practices that lead to
HCV outbreaks. Most clusters of HCV were associated with
multiple breaches in infection control practices. The potential
breaches described in these outbreaks demonstrate the follow-
ing common themes: (1) use of multidose vials generally for
heparin or saline administration; (2) poor compliance with
hand hygiene before and after each patient contact or after
touching a possibly contaminated surface; (3) failure to change
gloves when moving between patients or between patients and
potentially contaminated surfaces; (4) failure to adequately
disinfect environmental surfaces; (5) unsafe injection practices;
(6) failure to disinfect shared equipment between patient uses;
(6) lack of a separate area for medication preparation; and
(7) failure to have clearly separated clean and dirty utility rooms.
Reviews of outbreak investigations between 1998 and 2008
revealed similar deficiencies in infection control practices.21
These outbreaks also demonstrate the importance of using
molecular methods in outbreak investigations of HCV out-
breaks related to dialysis. In many cases, multiple small clusters
were demonstrated rather than a single large clonal cluster.
preventing hcv transmission during
dialysis
Detailed recommendations are available from the CDC for
preventing the transmission of infections among chronic





Analysis Potential Breaches Identified
Savey, 200511 France 22 Yes Lack of adequate space between bays; lack of space for preparing infusions and injections;
low nurse-to-patient ratio; inadequate training of staff; noncompliance with HH and
proper glove use; sharing of equipment among patients (eg, scissors); lack of routine
surface decontamination
Kondili, 200612 Italy 4 Yes Use of multidose vials of heparin
Spada, 200813 Italy 4 Yes Mechanism of transmission unclear
CDC, 200914 United
States
9 Yes Failure to test patients for HCV; inadequate cleaning and disinfection practices (visible
blood remained on surfaces); poor compliance with HH; failure to change gloves
between patients; lack of separate clean area for medication storage
Lanini, 201015 Italy 13 Yes Source likely contamination of a multidose heparin via use of multidose vials of saline;
poor compliance with HH; failure to change gloves between patients
Roy, 201216 Spain 2 Yes Poor compliance with HH and glove use; multidose heparin vials; lack of adequate space
between dialysis bays; source likely an infected HCP
Szucs, 201417 Hungary 17 Yes Multidose vials of heparin and saline
Rao, 201418 United
States
8 Yes Multidose vials of heparin, poor compliance with HH (73%) and glove use (72%); failure
to disinfect venous ports and medication vial prior to accessing; multidose vials stored




18 Yes Poor compliance with HH (82%); failure to change gloves between machines; clinic did
not clearly label clean and dirty sinks; failure to disinfect hubs and vial tops;
medication preparation next to a sink; failure to maintain asepsis when accessing
vascular devices; ineffective surface disinfection; failure to disinfect priming buckets
Aho, 201520 France 1 Yes Transmission felt due to failure to perform HH and/or transmission by instruments (eg,
scissors, clamps, etc.)
NOTE. HCP, healthcare provider; HCV, hepatitis C virus; HH, hand hygiene.
aCases may have been distributed among multiple clusters as identified by molecular analysis; not all patients identified may have been linked to
the outbreak(s).
hemodialysis patients;22 they have been updated by the CDC to
clarify guidance on parenteral medical vial.23 Strict adherence
to these guidelines should prevent person-to-person
transmission of HCV in hemodialysis centers. Furthermore,
recent advances in therapy for hepatitis C have demonstrated
that direct acting antiviral regimens are safe and highly
effective for treating HCV-infected patients on hemodialysis.24
Thus, screening and identification of HCV in hemodialysis
patients with consideration for treatment could further
decrease the risk of transmission within dialysis units.
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